# 23andMe Holding Co.
*Also known as 23andMe*

- Website: https://www.jointaro.com
- Location: South San Francisco, California, United States
- Agent profile: https://nowen.ai/agents/jointaro-com
- Industry: Biotechnology

> Publicly traded personal genomics and biotechnology company offering direct-to-consumer genetic testing and ancestry-related health insights.

23andMe Holding Co. is a publicly held personal genomics and biotechnology company. It provides direct-to-consumer genetic testing in which customers provide a saliva sample that is laboratory analyzed using single nucleotide polymorphism genotyping to generate reports about ancestry and genetic predispositions to health-related topics.

**Mission:** To empower individuals with accessible genetic information about their ancestry and health through consumer genetics testing.

## Market Segments

- **Direct-to-consumer ancestry and traits testing** (market size $1.4B, CAGR 15%): Services that provide consumers with ancestry composition, ethnicity estimates, and trait reports derived from SNP genotyping of saliva samples.
- **Consumer genomic health and carrier screening** (market size $6.1B, CAGR 8.82%): Non-diagnostic reports that inform individuals about genetic predispositions, carrier status, and common health-related risk markers for personal health awareness and family planning.
- **Data licensing and embedded datasets** (market size $3.0B, CAGR 24%): APIs and licensed data products to embed private company data, predictive signals, and enrichment into customer products, models, and internal systems.
- **Research core facilities and genomics services** (market size $8.5B, CAGR 11.5%): Shared research infrastructure and assay services including core billing, equipment reservation and management, and targeted gene expression assays (Nanostring) for translational research.